48 results on '"Rous, Brian"'
Search Results
2. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018
- Author
-
Cook, Sam, Pethick, Joanna, Kibbi, Nour, Hollestein, Loes, Lavelle, Katrina, de Vere Hunt, Isabella, Turnbull, Clare, Rous, Brian, Husain, Akhtar, Burn, John, Lüchtenborg, Margreet, Santaniello, Francesco, McRonald, Fiona, Hardy, Steven, Linos, Eleni, Venables, Zoe, and Rajan, Neil
- Published
- 2023
- Full Text
- View/download PDF
3. cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
- Author
-
Louis, David N, Wesseling, Pieter, Aldape, Kenneth, Brat, Daniel J, Capper, David, Cree, Ian A, Eberhart, Charles, Figarella‐Branger, Dominique, Fouladi, Maryam, Fuller, Gregory N, Giannini, Caterina, Haberler, Christine, Hawkins, Cynthia, Komori, Takashi, Kros, Johan M, Ng, HK, Orr, Brent A, Park, Sung‐Hye, Paulus, Werner, Perry, Arie, Pietsch, Torsten, Reifenberger, Guido, Rosenblum, Marc, Rous, Brian, Sahm, Felix, Sarkar, Chitra, Solomon, David A, Tabori, Uri, Bent, Martin J, Deimling, Andreas, Weller, Michael, White, Valerie A, and Ellison, David W
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Rare Diseases ,Central Nervous System Neoplasms ,Humans ,Neoplasm Grading ,brain tumors ,central nervous system ,classification ,neoplasms ,Clinical Sciences ,Neurosciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT-NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles-relating to classification categories, approaches to classification, nomenclature, and grading-that the group hopes will also inform the future classification of CNS neoplasms.
- Published
- 2020
4. Risk factors for metastatic cutaneous squamous cell carcinoma: Refinement and replication based on 2 nationwide nested case-control studies
- Author
-
Tokez, Selin, Venables, Zoe C., Hollestein, Loes M., Qi, Hongchao, Bramer, Edo M., Rentroia-Pacheco, Barbara, van den Bos, Renate R., Rous, Brian, Leigh, Irene M., Nijsten, Tamar, Mooyaart, Antien L., and Wakkee, Marlies
- Published
- 2022
- Full Text
- View/download PDF
5. Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study
- Author
-
Exarchakou, Aimilia, Papacleovoulou, Georgia, Rous, Brian, Magadi, Winnie, Rachet, Bernard, Neoptolemos, John P., and Coleman, Michel P.
- Published
- 2020
- Full Text
- View/download PDF
6. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study
- Author
-
Cabasag, Citadel J., Butler, John, Arnold, Melina, Rutherford, Mark, Bardot, Aude, Ferlay, Jacques, Morgan, Eileen, Møller, Bjørn, Gavin, Anna, Norell, Charles H., Harrison, Samantha, Saint-Jacques, Nathalie, Eden, Michael, Rous, Brian, Nordin, Andy, Hanna, Louise, Kwon, Janice, Cohen, Paul A., Altman, Alon D., Shack, Lorraine, Kozie, Serena, Engholm, Gerda, De, Prithwish, Sykes, Peter, Porter, Geoff, Ferguson, Sarah, Walsh, Paul, Trevithick, Richard, Tervonen, Hanna, O'Connell, Dianne, Bray, Freddie, and Soerjomataram, Isabelle
- Published
- 2020
- Full Text
- View/download PDF
7. Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting
- Author
-
Louis, David N., Wesseling, Pieter, Brandner, Sebastian, Brat, Daniel J., Ellison, David W., Giangaspero, Felice, Hattab, Eyas M., Hawkins, Cynthia, Judge, Meagan J., Kleinschmidt-DeMasters, Bette, Komori, Takashi, McLean, Catriona, Paulus, Werner, Perry, Arie, Reifenberger, Guido, Weller, Michael, and Rous, Brian
- Subjects
Cancer ,Medical research ,Epidemiology ,Central nervous system ,Brain tumors ,Web sites (World Wide Web) ,Clinical trials ,Health ,Benchmarking ,Tumors ,Public health ,Nervous system tumors ,Health ,World Health Organization - Abstract
* Context.--Standards for pathology reporting of cancer are foundational to national and international benchmarking, epidemiology, and clinical trials, with international standards for pathology reporting of cancer being undertaken through the International Collaboration on Cancer Reporting (ICCR). Objective.--To develop standardized templates for brain tumor diagnostic pathology reporting. Design.--As a response to the 2016 updated 4th edition of the WHO (World Health Organization) Classification of Tumours of the Central Nervous System (2016 CNS WHO), an expert ICCR committee developed data sets to facilitate reporting of brain tumors that are classified histologically and molecularly by the 2016 CNS WHO; as such, this represents the first combined histologic and molecular ICCR data set, and required a novel approach with 3 highly related data sets that should be used in an integrated manner. Results.--The current article and accompanying ICCR Web site describe reporting data sets for central nervous system tumors in the hope that they provide easy-to-use and highly reproducible means to issue diagnostic reports in consort with the 2016 CNS WHO. Conclusions.--The consistent use of these templates will undoubtedly prove useful for patient care, clinical trials, epidemiologic studies, and monitoring of neuro-oncologic care around the world. (Arch Pathol Lab Med. 2020;144:196-206; doi: 10.5858/arpa.2018-0565-OA), The value of a structured or synoptic approach to cancer reporting, leading to improvement in the quality and completeness of pathology cancer reports, has been recognized through many studies (1-4) [...]
- Published
- 2020
- Full Text
- View/download PDF
8. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies
- Author
-
Wang, Linyuan, Piskorz, Anna, Bosse, Tjalling, Jimenez-Linan, Mercedes, Rous, Brian, Gilks, C. Blake, Brenton, James D., Singh, Naveena, and Köbel, Martin
- Published
- 2022
- Full Text
- View/download PDF
9. Global Consultation on Cancer Staging: promoting consistent understanding and use
- Author
-
Brierley, James, O’Sullivan, Brian, Asamura, Hisao, Byrd, David, Huang, Shao Hui, Lee, Anne, Piñeros, Marion, Mason, Malcolm, Moraes, Fabio Y., Rösler, Wiebke, Rous, Brian, Torode, Julie, van Krieken, J. Han, and Gospodarowicz, Mary
- Published
- 2019
- Full Text
- View/download PDF
10. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
- Author
-
Genus, Tracey S. E., Bouvier, Catherine, Wong, Kwok F., Srirajaskanthan, Rajaventhan, Rous, Brian A., Talbot, Denis C., Valle, Juan W., Khan, Mohid, Pearce, Neil, Elshafie, Mona, Reed, Nicholas S., Morgan, Eileen, Deas, Andrew, White, Ceri, Huws, Dyfed, and Ramage, John
- Published
- 2019
- Full Text
- View/download PDF
11. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
- Author
-
Rindi, Guido, Klimstra, David S., Abedi-Ardekani, Behnoush, Asa, Sylvia L., Bosman, Frederik T., Brambilla, Elisabeth, Busam, Klaus J., de Krijger, Ronald R., Dietel, Manfred, El-Naggar, Adel K., Fernandez-Cuesta, Lynnette, Klöppel, Günter, McCluggage, W.Glenn, Moch, Holger, Ohgaki, Hiroko, Rakha, Emad A., Reed, Nicholas S., Rous, Brian A., Sasano, Hironobu, Scarpa, Aldo, Scoazec, Jean-Yves, Travis, William D., Tallini, Giovanni, Trouillas, Jacqueline, van Krieken, J.Han, and Cree, Ian A.
- Published
- 2018
- Full Text
- View/download PDF
12. Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer
- Author
-
Kortekaas, Kim E., Van de Vijver, Koen K., van Poelgeest, Mariëtte I.E., Gilks, C. Blake, Smit, Vincent T.H.B.M., Arif, Saimah, Arora, Deep, Faruqi, Asma, Ganesan, Raji, Griffin, Nicholas R., Hale, Richard, Hock, Yelin E., Horn, Lars-Christian, McCluggage, W. Glenn, Mukonoweshuro, Pinias, Park, Kay J., Rous, Brian, Tanchel, Bruce, Van Rompuy, Anne-Sophie, van Schalkwyk, Gerry, Vella, Jo, Vergine, Marco, Singh, Naveena, and Bosse, Tjalling
- Published
- 2020
- Full Text
- View/download PDF
13. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study
- Author
-
Funston, Garth, Hamilton, Willie, Abel, Gary, Crosbie, Emma J., Rous, Brian, Walter, Fiona M., Misra, Adya, Veitch, Emma, and Stone, Clare
- Subjects
Tumor antigens -- Usage -- Measurement ,Ovarian cancer -- Diagnosis ,Primary health care -- Methods ,Biological sciences - Abstract
Background The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for possible ovarian cancer in symptomatic women presenting to primary care. However, its diagnostic performance in this setting is unknown. We evaluated the performance of CA125 in primary care for the detection of ovarian and non-ovarian cancers. Methods and findings We studied women in the United Kingdom Clinical Practice Research Datalink with a CA125 test performed between 1 May 2011-31 December 2014. Ovarian and non-ovarian cancers diagnosed in the year following CA125 testing were identified from the cancer registry. Women were categorized by age: A total of 50,780 women underwent CA125 testing; 456 (0.9%) were diagnosed with ovarian cancer and 1,321 (2.6%) with non-ovarian cancer. Of women with a CA125 level [greater than or equal to]35 U/ml, 3.4% aged Conclusions CA125 is a useful test for ovarian cancer detection in primary care, particularly in women [greater than or equal to]50 years old. Clinicians should also consider non-ovarian cancers in women with high CA125 levels, especially if ovarian cancer has been excluded, in order to prevent diagnostic delay. Our results enable clinicians and patients to determine the estimated probability of ovarian cancer and all cancers at any CA125 level and age, which can be used to guide individual decisions on the need for further investigation or referral., Author(s): Garth Funston 1,*, Willie Hamilton 2, Gary Abel 2, Emma J. Crosbie 3,4, Brian Rous 5, Fiona M. Walter 1 Introduction Ovarian cancer is the eighth most common cancer [...]
- Published
- 2020
- Full Text
- View/download PDF
14. Second Primary Malignancies in Patients with a Neuroendocrine Neoplasm in England.
- Author
-
Russell, Beth, White, Benjamin E, Rous, Brian, Wong, Kwok, Bouvier Ellis, Catherine, Srirajaskanthan, Rajaventhan, Van Hemelrijck, Mieke, and Ramage, John K
- Subjects
SECONDARY primary cancer ,NEUROENDOCRINE tumors ,NOSOLOGY ,SMALL intestine ,STOMACH cancer ,PROSTATE cancer ,THYROID cancer - Abstract
Introduction: Patients with neuroendocrine neoplasms (NENs) may often develop other malignancies. This study aimed to identify the frequency at which these second malignancies occurred in England. Methods: Data were extracted from the National Cancer Registration and Analysis Service (NCRAS) on all patients diagnosed with a NEN at one of eight NEN site groups between 2012 and 2018: appendix, caecum, colon, lung, pancreas, rectum, small intestine, and stomach. WHO International Classification of Disease Edition-10 (ICD-10) codes were used to identify patients who had been diagnosed with an additional non-NEN cancer. Standardized incidence ratios (SIRs) for tumours diagnosed after the index NEN were produced for each non-NEN cancer type by sex and site. Results: A total of 20,579 patients were included in the study. The most commonly occurring non-NEN cancers after NEN diagnosis were the prostate (20%), lung (20%), and breast (15%). Statistically significant SIRs were observed for non-NEN cancer of the lung (SIR = 1.85, 95% CI: 1.55–2.22), colon (SIR = 1.78, 95% CI: 1.40–2.27), prostate (SIR = 1.56, 95% CI: 1.31–1.86), kidney (SIR = 3.53, 95% CI: 2.72–4.59), and thyroid (SIR = 6.31, 95% CI: 4.26–9.33). When stratified by sex, statistically significant SIRs remained for the lung, renal, colon, and thyroid tumours. Additionally, females had a statistically significant SIR for stomach cancer (2.65, 95% CI: 1.26–5.57) and bladder cancer (SIR = 2.61, 95% CI: 1.36–5.02). Conclusion: This study found that patients with a NEN experienced a metachronous tumour of the lung, prostate, kidney, colon, and thyroid at a higher rate than the general population of England. Surveillance and engagement in existing screening programmes are required to enable earlier diagnosis of second non-NEN tumours in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. 'Get Data Out' Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013–2019 in England.
- Author
-
Bodegraven, Birgitta van, Vernon, Sally, Eversfield, Charlotte, Board, Ruth, Craig, Paul, Gran, Sonia, Harwood, Catherine A, Keohane, Stephen, Levell, Nick J, Matin, Rubeta N, Proby, Charlotte, Rajan, Neil, Rous, Brian, Ascott, Anna, Millington, George W M, Venables, Zoe C, and Committee, the British Association of Dermatologists National Disease Registration Service Steering
- Subjects
SKIN cancer ,MERKEL cell carcinoma ,BASAL cell carcinoma ,SURVIVAL rate ,TUMORS ,PRECANCEROUS conditions - Abstract
Background Providing detailed skin cancer statistics, including incidence and survival, by tumour type and patient characteristics is important for up-to-date epidemiological information. Objectives To create a new clinically relevant consensus-based classification for registered skin tumours using tumour type and patient characteristics and to describe its application to all registered tumours in England between 2013 and 2019. Methods Tumours with skin topographical codes (ICD-10) and morphology and behaviour (ICD-O3) were grouped together in an iterative process creating a hierarchical tree structure. The primary-level grouping partitioned skin tumours into skin cancer, melanoma in situ , extramammary Paget disease (EMPD) and tumours of uncertain malignant potential. Second-level groups split skin cancer into keratinocyte cancer (KC), melanoma and rare cancers. The third-level group split KC into basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC). Further groups were split into genital or non-genital, first or subsequent tumour, age, gender, stage, or National Health Service (NHS) region. Incidence counts, Kaplan–Meier and net survival estimates and referral routes [two-week wait (TWW), general practitioner (GP), outpatient] categorisations were calculated for each grouping across all years. Results A total of 1 445 377 skin cancers and 49 123 precancerous lesions and undefined entities were registered in England between 2013 and 2019. Skin tumours and skin cancer incidence rates are increasing for most tumour types. The most common type of skin cancer was BCC with an incidence rate of 282.36 per 100 000 person-years (PYs) [ n = 158 934, 95% confidence interval (CI) 280.98–283.76] in 2019, followed by cSCC with an incidence rate of 85.24 per 100 000 PYs (n = 47 977, 95% CI 84.48–86.00) and melanoma with 27.24 (n = 15 332, 95% CI 26.81–27.67) per 100 000 PYs. Each year approximately 1800 rare skin cancers, 1500 genital cSCCs and 100 cases of EMPD are registered. Of 15 000 melanoma cases, 120 cases of melanoma occur in individuals aged < 25 years annually. One-year and five-year overall net survival varies by tumour type. cSCC 5-year net survival (89.8%, 95% CI 88.8–90.9) was comparable to the net survival of all melanomas (89.6%, 95% CI 88.7–90.6). BCC had excellent survival (overall net survival > 100%). Patients with late-stage melanoma, Merkel cell carcinoma and genital cSCC have a 5-year net survival < 60%. Older patients received fewer TWW referrals than their younger counterparts with the same tumour type at the same location. Patients with acral lentiginous melanoma had fewer TWW referrals and more standard GP referrals than patients with common melanomas. Conclusions 'Get Data Out' Skin provides detailed and up-to-date statistics on all registrable skin tumours in England, including for the first time precancerous lesions and rare subtypes of common cancers. These data can be used by clinicians, researchers and commissioners to better understand skin cancer and improve resource allocation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Incidence and survival of soft tissue sarcoma in England between 2013 and 2017, an analysis from the National Cancer Registration and Analysis Service.
- Author
-
Bacon, Andrew, Wong, Kwok, Fernando, Malee S., Rous, Brian, Hill, Roger J. W., Collins, Shane D., Broggio, John, and Strauss, Sandra J.
- Subjects
SARCOMA ,LIPOSARCOMA ,TISSUE viability ,GASTROINTESTINAL stromal tumors ,PROPORTIONAL hazards models ,NOSOLOGY - Abstract
There is a paucity of population‐based data detailing the incidence and survival of patients with soft tissue sarcoma (STS), in part due to the heterogeneity of disease and changes to classification. Here, the incidence and survival of all STS subtypes registered in England between 2013 and 2017 were analysed using cancer registry data held by the National Cancer Registration and Analysis Service. Age‐standardised incidence rates were calculated per 1 000 000 using the 2013 European Standard Population. Net survival was computed using Brenner's alternative method, with the Ederer II estimator. Age‐specific overall survival was assessed using Kaplan‐Meier. The influence of age, sex, socioeconomic deprivation and diagnostic routes on survival was assessed using Cox proportional hazards modelling. In total, 19 717 patients were diagnosed with STS, an average of 3943 patients per year and representing approximately 0.8% of malignancies. The most common histological diagnoses were Gastrointestinal Stromal Tumours (GIST), leiomyosarcoma and undifferentiated sarcoma, accounting for 20.2%, 13.3% and 12.7% of all sarcomas, respectively. Five‐year net survival for all malignant STS was 65.0%; and was lowest for patients with vascular tumours at 39%. Patients from most deprived cohorts had 23% greater chance of dying within 5 years than patients in least deprived areas. This population‐based study has allowed us for the first time to define the incidence and survival rates of prevalent STS subtypes in England such as GIST, liposarcoma and leiomyosarcoma, as well as rare entities and groups with inferior outcome. This data is invaluable for service provision, benchmarking and addressing inequality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Organ Transplants From Deceased Donors With Primary Brain Tumors and Risk of Cancer Transmission.
- Author
-
Greenhall, George H. B., Rous, Brian A., Robb, Matthew L., Brown, Chloe, Hardman, Gillian, Hilton, Rachel M., Neuberger, James M., Dark, John H., Johnson, Rachel J., Forsythe, John L. R., Tomlinson, Laurie A., Callaghan, Chris J., and Watson, Christopher J. E.
- Published
- 2023
- Full Text
- View/download PDF
18. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012–2018: A Retrospective, Population-Based Study.
- Author
-
White, Benjamin E., Russell, Beth, Remmers, Sebastiaan, Rous, Brian, Chandrakumaran, Kandiah, Wong, Kwok F., Van Hemelrijck, Mieke, Srirajaskanthan, Rajaventhan, and Ramage, John K.
- Subjects
REPORTING of diseases ,STOMACH tumors ,INTESTINAL tumors ,COLON tumors ,PANCREATIC tumors ,MULTIVARIATE analysis ,RECTUM tumors ,RETROSPECTIVE studies ,LUNG tumors ,SEX distribution ,CANCER patients ,TUMOR classification ,NEUROENDOCRINE tumors ,FACTOR analysis ,OVERALL survival - Abstract
Simple Summary: We conducted a retrospective, population-based study comparing overall survival (OS) between males and females with neuroendocrine neoplasia (NEN). In total, 14,834 cases of NEN recorded in England's National Cancer Registry and Analysis Service (NCRAS)), were analysed. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Females displayed increased survival irrespective of the stage, morphology or level of deprivation, which was statistically significant in NEN of the lung, pancreas, rectum and stomach (p < 0.001). Stage of tumour mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. Females diagnosed with NEN tend to survive longer than males, and stage at presentation only accounts for part of this effect. Future research in NEN, as well as prognostication and treatment, should consider sex as an important factor. Pre-clinical studies have suggested sex hormone signalling pathways may influence tumorigenesis in neuroendocrine neoplasia (NEN). We conducted a retrospective, population-based study to compare overall survival (OS) between males and females with NEN. A total of 14,834 cases of NEN diagnosed between 2012 and 2018, recorded in England's National Cancer Registry and Analysis Service (NCRAS), were analysed. The primary outcome was OS with 5 years maximum follow-up. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Appendiceal, pulmonary and early-stage NEN were most commonly diagnosed in females; stomach, pancreatic, small intestinal, colonic, rectal and later-stage NEN were more often diagnosed in males. Females displayed increased survival irrespective of the stage, morphology or level of deprivation. On average, they survived 3.62 (95% CI 1.73–5.90) to 10.26 (6.6–14.45) months longer than males; this was statistically significant in NEN of the lung, pancreas, rectum and stomach (p < 0.001). The stage mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. The reasons underlying these differences are not yet understood. Overall, females diagnosed with NEN tend to survive longer than males, and the stage at presentation only partially explains this. Future research, as well as prognostication and treatment, should consider sex as an important factor. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. FIGO 2023 endometrial cancer staging system: recommendations for the UK.
- Author
-
Wong, Jason, Bani‐Khalid, Aseel, Ganesan, Raji, Rous, Brian, Arora, Rupali, Dobbs, Stephen, and McCluggage, W Glenn
- Subjects
ENDOMETRIAL cancer ,TUMOR classification ,RECOMMENDER systems ,GYNECOLOGIC cancer ,BREAST ,INTERNET surveys - Abstract
The International Federation of Gynaecology and Obstetrics (FIGO) updated its staging system for endometrial cancer in June 2023. The new system includes nonanatomic histological parameters and molecular classification, which are not traditionally part of staging systems. In August 2023, a survey was conducted among pathologists and clinicians to determine their views on adopting the FIGO 2023 system in the UK. The results showed no consensus on whether to incorporate the new parameters into staging, and only 34% of respondents favored adopting FIGO 2023. Access to timely molecular testing was identified as a factor that correlated with support for adoption. The British Association of Gynaecological Pathologists (BAGP) and British Gynaecological Cancer Society (BGCS) currently do not recommend adopting FIGO 2023 in the UK due to controversies and limited access to molecular classification. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
20. Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019.
- Author
-
Liu, Hanhua, Stiller, Charles A., Crooks, Colin J., Rous, Brian, Bythell, Mary, Broggio, John, Rankin, Judith, Nanduri, Vasanta, Lanyon, Peter, Card, Tim R., Ban, Lu, Elliss‐Brookes, Lucy, Broughan, Jennifer M., Paley, Lizz, Wong, Kwok, Bacon, Andrew, Bishton, Mark, and West, Joe
- Subjects
LANGERHANS-cell histiocytosis ,OVERALL survival ,NOSOLOGY ,TUMOR classification - Abstract
Summary: This analysis is the largest population‐based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD‐O‐3) coded Langerhans cell histiocytosis (LCH) from England. People of all ages were identified from the National Cancer Registration Dataset using ICD‐O‐3 morphologies 9751–9754 for neoplasms diagnosed in 2013–2019. A total of 658 patients were identified, of whom 324 (49%) were children aged <15 years. The age‐standardised incidence rate was 4.46 (95% confidence interval [CI] 3.99–4.98) per million children and 1.06 (95% CI 0.94–1.18) per million adults aged ≥15 years. Prevalence of LCH was 9.95 (95% CI 9.14–10.81) per million persons at the end of 2019. The 1‐year overall survival (OS) was 99% (95% CI 97%–100%) for children and 90% (95% CI 87%–93%) for adults. Those aged ≥60 years had poorer OS than those aged <15 years (hazard ratio [HR] 22.12, 95% CI 7.10–68.94; p < 0.001). People in deprived areas had lower OS than those in the least deprived areas (HR 5.36, 95% CI 1.16–24.87; p = 0.03). There will inevitably be other environmental factors and associations yet to be identified, and the continued standardised data collection will allow further evaluation of data over time. This will be increasingly important with developments in LCH management following the large collaborative international trials such as LCH IV. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Stage–specific incidence trends of renal cancers in the East of England, 1999–2016
- Author
-
Herbert, Annie, Barclay, Matthew E., Koo, Minjoung M., Rous, Brian, Greenberg, David C., Abel, Gary, and Lyratzopoulos, Georgios
- Published
- 2021
- Full Text
- View/download PDF
22. Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry.
- Author
-
Palmer, Kieran, Weerasuriya, Scott, Chandrakumaran, Kandiah, Rous, Brian, White, Benjamin E., Paisey, Sangeeta, Srirajaskanthan, Rajaventhan, and Ramage, John K.
- Subjects
KAPLAN-Meier estimator ,ADENOCARCINOMA ,SURVIVAL rate ,OVERALL survival ,REGRESSION analysis - Abstract
Background: Goblet cell adenocarcinoma (GCA) of the appendix is a rare and aggressive tumour with varying nomenclature and classification systems. This has led to heterogeneity in published data, and there is a lack of consensus on incidence, survival, and management. Methods: We provide an overview of GCA with a comprehensive systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology and a retrospective analysis of all cases recorded in the English National Cancer Registration and Analysis Service database between 1995 and 2018. The Kaplan-Meier estimator was used to calculate overall survival, and Cox proportional hazards regression was used to identify prognostic factors. Results: The systematic review demonstrated an incidence of 0.05-0.3 per 100,000 per year among North American registry studies. The 1-, 3-, and 5-year survival rate was 95.5%, 85.9%-87.6%, and 76.0%-80.6%, respectively. Age, stage, and grade were identified as prognostic factors for survival. Our analysis included 1,225 cases. Agestandardised incidence was 0.0335 per year in 1995 and gradually rose to 0.158 per year in 2018. The 1-, 3-, and 5-year survival rate was 90.0% [95% confidence interval (95% CI): 85.4-94.0], 76.0% (95% CI: 73.8-80.9), and 68.6% (95% CI: 65.9-72.2), respectively. On univariate Cox regression analyses, female sex, stage, and grade were associated with worse overall survival. On multivariate analysis, only stage remained a statistically significant prognostic factor. Conclusions: GCA of the appendix is rare, but incidence is increasing. We report a lower incidence and survival than North American registry studies. Higher stage was associated with decreased survival. Further prospective studies are required to establish optimal management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data*.
- Author
-
Venables, Zoe Claire, Tokez, Selin, Hollestein, Loes M., Mooyaart, Antien L., van den Bos, Renate Ruth, Rous, Brian, Leigh, Irene M., Nijsten, Tamar, and Wakkee, Marlies
- Subjects
SQUAMOUS cell carcinoma ,WOMEN'S hospitals ,REPORTING of diseases - Abstract
Summary: Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer worldwide with relatively low metastatic potential (2–5%). Developments in therapeutic options have highlighted the need to better identify high‐risk patients who could benefit from closer surveillance, adjuvant therapies and baseline/follow‐up imaging, while at the same time safely omitting low‐risk patients from further follow‐up. Controversy remains regarding the predictive performance of current cSCC staging systems and which methodology to adopt. Objectives: To validate the performance of four cSCC staging systems [American Joint Committee on Cancer 8th edition (AJCC8), Brigham and Women's Hospital (BWH), Tübingen and Salamanca T3 refinement] in predicting metastasis using a nationwide cohort. Methods: A nested case–control study using data from the National Disease Registration Service, England, 2013–2015 was conducted. Metastatic cSCC cases were identified using an algorithm to identify all potential cases for manual review. These were 1 : 1 matched on follow‐up time to nonmetastatic controls randomly selected from 2013. Staging systems were analysed for distinctiveness, homogeneity, monotonicity, specificity, positive predictive value (PPV), negative predictive value (NPV) and c‐index. Results: We included 887 metastatic cSCC cases and 887 nonmetastatic cSCC controls. The BWH system showed the highest specificity [92.8%, 95% confidence interval (CI) 90.8–94.3%, PPV (13.2%, 95% CI 10.6–16.2) and c‐index (0.84, 95% CI 0.82–0.86). The AJCC8 showed superior NPV (99.2%, 95% CI 99.2–99.3), homogeneity and monotonicity compared with the BWH and Tübingen diameter and thickness classifications (P < 0.001). Salamanca refinement did not show any improvement in AJCC8 T3 cSCC staging. Conclusions: We validated four cSCC staging systems using the largest nationwide dataset of metastatic cSCC so far. Although the BWH system showed the highest overall discriminative ability, PPV was low for all staging systems, which shows the need for further improvement and refining of current cSCC staging systems. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Vet-ICD-O-Canine-1, a System for Coding Canine Neoplasms Based on the Human ICD-O-3.2.
- Author
-
Pinello, Katia, Baldassarre, Valeria, Steiger, Katja, Paciello, Orlando, Pires, Isabel, Laufer-Amorim, Renée, Oevermann, Anna, Niza-Ribeiro, João, Aresu, Luca, Rous, Brian, Znaor, Ariana, Cree, Ian A., Guscetti, Franco, Palmieri, Chiara, and Dagli, Maria Lucia Zaidan
- Subjects
REPORTING of diseases ,PUBLIC health surveillance ,OCCUPATIONAL roles ,NOSOLOGY ,ANIMAL experimentation ,DESCRIPTIVE statistics ,TUMORS ,DOGS ,MEDICAL coding - Abstract
Simple Summary: The development of a widely accepted and comparable animal cancer registration system lacks standardized animal cancer coding. The GIVCS group have developed a comparative coding system for canine neoplasms—Vet-ICD-O-canine-1—compatible with the human ICD-O-3.2 and consistent with the currently recognized classification schemes for canine tumors. This system comprises 335 topography codes and 534 morphology codes allowing the collection of consistent epidemiologic canine cancer data and offering a robust framework for comparative oncology studies. Cancer registries are fundamental tools for collecting epidemiological cancer data and developing cancer prevention and control strategies. While cancer registration is common in the human medical field, many attempts to develop animal cancer registries have been launched over time, but most have been discontinued. A pivotal aspect of cancer registration is the availability of cancer coding systems, as provided by the International Classification of Diseases for Oncology (ICD-O). Within the Global Initiative for Veterinary Cancer Surveillance (GIVCS), established to foster and coordinate animal cancer registration worldwide, a group of veterinary pathologists and epidemiologists developed a comparative coding system for canine neoplasms. Vet-ICD-O-canine-1 is compatible with the human ICD-O-3.2 and is consistent with the currently recognized classification schemes for canine tumors. It comprises 335 topography codes and 534 morphology codes. The same code as in ICD-O-3.2 was used for the majority of canine tumors showing a high level of similarity to their human counterparts (n = 408). De novo codes (n = 152) were created for specific canine tumor entities (n = 126) and topographic sites (n = 26). The Vet-ICD-O-canine-1 coding system represents a user-friendly, easily accessible, and comprehensive resource for developing a canine cancer registration system that will enable studies within the One Health space. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
- Author
-
Girardi, Fabio, Rous, Brian, Stiller, Charles A, Gatta, Gemma, Fersht, Naomi, Storm, Hans H, Rodrigues, Jessica R, Herrmann, Christian, Marcos-Gragera, Rafael, Peris-Bonet, Rafael, Valkov, Mikhail, Weir, Hannah K, Woods, Ryan R, You, Hui, Cueva, Patricia A, De, Prithwish, Carlo, Veronica Di, Johannesen, Tom Børge, Lima, Carlos A, and Lynch, Charles F
- Published
- 2021
- Full Text
- View/download PDF
26. Non-endoscopic immunocytological screening test for Barrett’s oesophagus
- Author
-
Lao-Sirieix, Pierre, Rous, Brian, O’Donovan, Maria, Hardwick, Richard H, Debiram, Irene, and Fitzgerald, Rebecca C
- Published
- 2007
27. Differential Use of Two AP-3-mediated Pathways by Lysosomal Membrane Proteins
- Author
-
Ihrke, Gudrun, Kyttälä, Aija, Russell, Matthew R. G., Rous, Brian A., and Luzio, J. Paul
- Published
- 2004
28. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records.
- Author
-
Funston, Garth, Mounce, Luke TA, Price, Sarah, Rous, Brian, Crosbie, Emma J, Hamilton, Willie, and Walter, Fiona M
- Subjects
CANCER diagnosis ,OVARIAN cancer ,ELECTRONIC health records ,DIAGNOSIS ,COHORT analysis ,SYMPTOMS - Abstract
Background: In the UK, the cancer antigen 125 (CA125) test is recommended as a first-line investigation in women with symptoms of possible ovarian cancer.Aim: To compare time between initial primary care CA125 test and diagnosis, tumour morphology, and stage in women with normal (<35 U/ml) and abnormal (≥35 U/ml) CA125 levels prior to ovarian cancer diagnosis.Design and Setting: Retrospective cohort study using English primary care and cancer registry data.Method: Associations between CA125 test results and test-to-diagnosis interval, stage, and ovarian cancer morphology were examined.Results: In total, 456 women were diagnosed with ovarian cancer in the 12 months after having a CA125 test. Of these, 351 (77%) had an abnormal, and 105 (23%) had a normal, CA125 test result. The median test-to-diagnosis interval was 35 days (interquartile range [IQR] 21-53) for those with abnormal CA125 levels, and 64 days (IQR 42-127) for normal CA125 levels. Tumour morphology differed by CA125 result: indolent borderline tumours were less common in those with abnormal CA125 levels (n = 47, 13%) than those with normal CA125 levels (n = 51, 49%) (P<0.001). Staging data were available for 304 women with abnormal, and 77 with normal, CA125 levels. Of those with abnormal CA125 levels, 35% (n = 106) were diagnosed at an early stage, compared to 86% (n = 66) of women with normal levels. The odds of being diagnosed with early-stage disease were higher in women with normal as opposed to abnormal CA125 levels (odds ratio 12.2, 95% confidence interval = 5.8 to 25.1, P<0.001).Conclusion: Despite longer intervals between testing and diagnosis, women with normal, compared with abnormal, CA125 levels more frequently had indolent tumours and were more commonly diagnosed at an early stage in the course of the disease. Although testing approaches that have greater sensitivity might expedite diagnosis for some women, it is not known if this would translate to earlier-stage diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
29. The International Collaboration for Cancer Classification and Research.
- Author
-
Cree, Ian A., Indave Ruiz, Blanca Iciar, Zavadil, Jiri, McKay, James, Olivier, Magali, Kozlakidis, Zisis, Lazar, Alexander J., Hyde, Chris, Holdenrieder, Stefan, Hastings, Ros, Rajpoot, Nasir, Fouchardiere, Arnaud, Rous, Brian, Zenklusen, Jean Claude, Normanno, Nicola, and Schilsky, Richard L.
- Subjects
TUMOR classification ,CANCER research ,INFORMATION overload ,CLASSIFICATION ,TRANSLATIONAL research - Abstract
Gaps in the translation of research findings to clinical management have been recognized for decades. They exist for the diagnosis as well as the management of cancer. The international standards for cancer diagnosis are contained within the World Health Organization (WHO) Classification of Tumours, published by the International Agency for Research on Cancer (IARC) and known worldwide as the WHO Blue Books. In addition to their relevance to individual patients, these volumes provide a valuable contribution to cancer research and surveillance, fulfilling an important role in scientific evidence synthesis and international standard setting. However, the multidimensional nature of cancer classification, the way in which the WHO Classification of Tumours is constructed, and the scientific information overload in the field pose important challenges for the translation of research findings to tumour classification and hence cancer diagnosis. To help address these challenges, we have established the International Collaboration for Cancer Classification and Research (IC3R) to provide a forum for the coordination of efforts in evidence generation, standard setting and best practice recommendations in the field of tumour classification. The first IC3R meeting, held in Lyon, France, in February 2019, gathered representatives of major institutions involved in tumour classification and related fields to identify and discuss translational challenges in data comparability, standard setting, quality management, evidence evaluation and copyright, as well as to develop a collaborative plan for addressing these challenges. What's new? The World Health Organization Classification of Tumours has been informing cancer research and clinical practice by providing an international consensus on the tumour criteria for cancer diagnosis. In a new initiative coordinated by the International Agency for Research on Cancer, major institutions are now joining forces to address the remaining challenges in translational research and facilitate the application of research results to clinical practice. The newly‐established International Collaboration for Cancer Classification and Research (IC3R) aims to provide a forum for the coordination of efforts in generating evidence, setting standards, and providing best practice recommendations for tumor classification and cancer research. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Chapter 3: Classification and coding.
- Author
-
Ferlay, Jacques, Kraywinkel, Klaus, Rous, Brian, and Znaor, Ariana
- Subjects
BENIGN tumors ,ANAPLASTIC large-cell lymphoma ,MULTIPLE myeloma ,ADULT T-cell leukemia ,BLADDER cancer - Abstract
The article informs that Cancer Incidence in Five Continents (CI5) series has followed the evolution of the International Classification of Diseases (ICD) through four revisions, from the seventh revision (ICD-7) to the tenth (ICD-10), and the creation of a coding scheme for oncology. It mentions that All data supplied for this volume either were already coded to ICD-O-3 when submitted, or were converted by IARC to ICD-O-3 for checking and were then converted to ICD-10 for presentation.
- Published
- 2021
31. Chapter 4: Histological groups.
- Author
-
Ferlay, Jacques and Rous, Brian
- Subjects
GRANULOSA cell tumors ,TESTIS tumors ,TRANSITIONAL cell carcinoma ,RENAL cell carcinoma ,SMALL cell carcinoma ,BASAL cell carcinoma ,INTRAHEPATIC bile ducts - Abstract
The article informs that the data presented in this volume of Cancer Incidence in Five Continents (CI5) cover the period 2008–2012 and are mainly organized by the predominantly site based categories of Chapter II (Neoplasms) of the 10th revision of the International Classification of Diseases. It mentions that main structure of the histological grouping is that specific types of malignant neoplasms are listed, as well as the category Unspecified malignant neoplasm.
- Published
- 2021
32. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
- Author
-
Singh, Naveena, Piskorz, Anna M, Bosse, Tjalling, Jimenez‐Linan, Mercedes, Rous, Brian, Brenton, James D, Gilks, C Blake, and Köbel, Martin
- Subjects
DNA polymerases ,CARCINOMA ,IMMUNOHISTOCHEMISTRY ,CLASSIFICATION algorithms ,NUCLEOTIDE sequencing - Abstract
TP53 mutations are considered a surrogate biomarker of the serous‐like 'copy number high' molecular subtype of endometrial carcinoma (EC). In ovarian carcinoma, p53 immunohistochemistry (IHC) accurately reflects mutational status with almost 100% specificity but its performance in EC has not been established. This study tested whether p53 IHC reliably predicts TP53 mutations identified by next‐generation sequencing (NGS) in EC biopsy samples for all ECs and as part of a molecular classification algorithm after exclusion of cases harbouring mismatch repair defects (MMRd) or pathogenic DNA polymerase epsilon exonuclease domain mutations (POLEmut). A secondary aim assessed inter‐laboratory variability in p53 IHC. From a total of 207 cases from five centres (37–49 cases per centre), p53 IHC carried out at a central reference laboratory was compared with local IHC (n = 164) and curated tagged‐amplicon NGS TP53 sequencing results (n = 177). Following consensus review, local and central p53 IHC results were concordant in 156/164 (95.1%) tumours. Discordant results were attributable to both interpretive and technical differences in staining between the local and central laboratories. When results were considered as any mutant pattern versus wild‐type pattern staining, however, there was disagreement between local and central review in only one case. The concordance between p53 IHC and TP53 mutation was 155/168 (92.3%) overall, and 117/123 (95.1%) after excluding MMRd and POLEmut EC. Three (3/6) discordant results were in serous carcinomas with complete absence of p53 staining but no detectable TP53 mutation. Subclonal mutant p53 IHC expression was observed in 9/177 (5.1%) cases, of which four were either MMRd or POLEmut. Mutant pattern p53 IHC was observed in 63/63 (100%) serous carcinomas that were MMR‐proficient/POLE exonuclease domain wild‐type. Optimised p53 IHC performs well as a surrogate test for TP53 mutation in EC biopsies, demonstrates excellent inter‐laboratory reproducibility, and has high clinical utility for molecular classification algorithms in EC. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Geographic variation in the use of lymphadenectomy and external-beam radiotherapy for endometrial cancer: a cross-sectional analysis of population-based data.
- Author
-
White, B, Nordin, A, Fry, A, Ahmad, A, McPhail, S, Roe, C, Rous, B, Smittenaar, R, Shelton, J, White, Becky, Nordin, Andy, Fry, Anna, Ahmad, Amar, McPhail, Sean, Roe, Catherine, Rous, Brian, Smittenaar, Rebecca, and Shelton, Jon
- Subjects
ENDOMETRIAL cancer ,CROSS-sectional method ,DATA analysis ,CANCER radiotherapy ,PHYSICIAN practice patterns - Abstract
Objective: To quantify geographic variation in the use of lymphadenectomy and/or external-beam radiotherapy (EBRT) for endometrial cancer in England.Design: Cross-sectional analysis of population-based data.Setting: English cancer registry data, linked to chemotherapy, radiotherapy and hospital episodes statistics data.Population: Twenty-two thousand four hundred and eighty-three women with endometrial cancer presenting without clinical or radiological evidence of distant metastatic spread, diagnosed in England from 2013 to 2016.Methods: Proportions of patients receiving lymphadenectomy and/or EBRT were compared across 19 Cancer Alliances, to identify variations in clinical practice. Two separate logistic regression models assessed the impact on variation of adjustment for tumour and patient characteristics.Main Outcome Measures: Receipt of lymphadenectomy, receipt of EBRT.Results: There was substantial variation by Cancer Alliance in the adjusted proportion of women with endometrial cancer receiving lymphadenectomy (range 5% [95% CI 4-6%] to 48% [95% CI 45-52%]) and EBRT (range 10% [95% CI 7-12%] to 31% [95% CI 28-33%]), after adjusting for variation in pathological grade, age, comorbidities, deprivation, ethnic group and (EBRT only) FIGO stage. Different approaches to clinical practice were identified; (i) one Cancer Alliance had significantly higher than average lymphadenectomy and significantly lower than average EBRT use, (ii) three had high use of both lymphadenectomy and EBRT, (iii) one had low lymphadenectomy use and high EBRT use, and (iv) three had low use of both lymphadenectomy and EBRT.Conclusions: Lymphadenectomy is probably used to triage for EBRT when lymphadenectomy use is high and EBRT use is low. This is probably a result of variation in local endometrial cancer management guidelines, suggesting that UK recommendations should be clarified.Tweetable Abstract: There is geographic variation in England in the use of lymphadenectomy and radiotherapy to treat endometrial cancer. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
34. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
- Author
-
Khan, Shahid A., Genus, Tracey, Morement, Helen, Murphy, Andrew, Rous, Brian, and Tataru, Daniela
- Published
- 2019
- Full Text
- View/download PDF
35. Reexamination of lead(II) coordination preferences in sulfur-rich sites: Implications for a critical mechanism of lead poisoning
- Author
-
Magyar, John S., Payne, John C., Penner-Hahn, James E., Tsu-Chien Weng, Bridgewater, Brian M., Godwin, Hilary Arnold, Stern, Charlotte M., Mijovilovich, Ana, Dye, David F., Parkin, Gerard, Rous, Brian W., and Zaleski, Jeffrey M.
- Subjects
Zinc compounds -- Chemical properties ,Zinc compounds -- Research ,Lead compounds -- Chemical properties ,Lead compounds -- Research ,Lead poisoning -- Research ,Chemistry - Abstract
The detailed structural studies of lead that provide critical insights into the mechanism by which lead alters the activity of the proteins containing thoi-rich structural zinc-binding sites is reported. Lead binds in a three-coordinate mode and in a geometry that is fundamentally different from the natural coordination of zinc in these sites, which explains why lead disrupts the structure of zinc-binding peptides and thus provides the first detailed molecular understanding of the development toxicity of lead.
- Published
- 2005
36. Spectroscopic determination of the binding affinity of zinc to the DNA-binding domains of nuclear hormone receptors
- Author
-
Payne, John C., Rous, Brian W., Tenderholt, Adam L., and Godwin, Hilary Arnold
- Subjects
Absorption spectra -- Analysis ,Hormone receptors -- Analysis ,Protein binding -- Analysis ,Structure-activity relationships (Biochemistry) -- Analysis ,Biological sciences ,Chemistry - Abstract
Metal-binding studies with DNA-binding domain of human estrogen receptor alpha and rat glucocorticoid receptor indicate that cobalt binds to both sites with similar affinities, while zinc binds to each of the two sites in the DNA-binding domains of steroid receptor. Data suggest there is hardly any interaction between the two metal sites in tems of metal binding.
- Published
- 2003
37. Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.
- Author
-
Venables, Zoë C., Autier, Philippe, Nijsten, Tamar, Wong, Kwok F., Langan, Sinéad M., Rous, Brian, Broggio, John, Harwood, Catherine, Henson, Katherine, Proby, Charlotte M., Rashbass, Jem, and Leigh, Irene M.
- Published
- 2019
- Full Text
- View/download PDF
38. Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
- Author
-
McCluggage, W. Glenn, Judge, Meagan J., Alvarado-Cabrero, Isabel, Duggan, Máire A., Horn, Lars-Christian, Pei Hui, Ordi, Jaume, Otis, Christopher N., Park, Kay J., Plante, Marie, Stewart, Colin J. R., Wiredu, Edwin K., Rous, Brian, and Hirschowitz, Lynn
- Published
- 2018
- Full Text
- View/download PDF
39. TNM clinical staging of prostate cancer: issues and solutions.
- Author
-
Varma, Murali, Cochlin, Dennis, Delahunt, Brett, Kynaston, Howard, Rees, John, Rous, Brian, and Narahari, Krishna
- Subjects
PROSTATE cancer - Abstract
The author comments on TNM clinical staging of prostate cancer. Topics discussed include Clinical staging is important in assessing the spread of prostate cancer because a final pathological stage would be available only in those patients who undergo radical prostatectomy; issue within the TNM system related to the sub-categorization of cT2 prostate cancer by magnetic resonance imaging; and difference between the Union for International Cancer Control and American Joint Committee on Cancer.
- Published
- 2019
- Full Text
- View/download PDF
40. Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses.
- Author
-
Gavin, Anna, Rous, Brian, Marcos-Gragera, Rafael, Middleton, Richard, Steliarova-Foucher, Eva, Maynadie, Marc, Zanetti, Roberto, and Visser, Otto
- Subjects
- *
MEDICAL protocols , *DIAGNOSIS , *HEMATOLOGIC malignancies , *THERAPEUTICS - Abstract
Haematological malignancies (HM) represent over 6% of the total cancer incidence in Europe and affect all ages, ranging between 45% of all cancers in children and 7% in the elderly. Thirty per cent of childhood cancer deaths are due to HM, 8% in the elderly. Their registration presents specific challenges, mainly because HM may transform or progress in the course of the disease into other types of HM. In the context of cancer registration decisions have to be made about classifying subsequent notifications on the same patient as the same tumour (progression), a transformation or a new tumour registration. Allocation of incidence date and method of diagnosis must also be standardised. We developed European Network of Cancer Registries (ENCR) recommendations providing specific advice for cancer registries to use haematology and molecular laboratories as data sources, conserve the original date of incidence in case of change of diagnosis, make provision for recording both the original as well as transformed tumour and to apply precise rules for recording and counting multiple diagnoses. A reference table advising on codes which reflect a potential transformation or a new tumour is included. This work will help to improve comparability of data produced by population-based cancer registries, which are indispensable for aetiological research, health care planning and clinical research, an increasing important area with the application of targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
41. Liver tumour pathology.
- Author
-
Rous, Brian and Davies, Susan E.
- Published
- 2007
- Full Text
- View/download PDF
42. Data Resource Profile: National Cancer Registration Dataset in England.
- Author
-
Henson, Katherine E, Elliss-Brookes, Lucy, Coupland, Victoria H, Payne, Elsita, Vernon, Sally, Rous, Brian, and Rashbass, Jem
- Subjects
CLINICAL trial registries ,RECORDING & registration ,AUTOPSY ,MEDICAL personnel ,MEDICAL registries ,CANCER ,MEDICAL care ,NURSE practitioners - Published
- 2020
- Full Text
- View/download PDF
43. Misinterpretation of the origins and composition of staging data and its impact on colorectal cancer survival.
- Author
-
Eden, Michael, Rous, Brian A., and Rashbass, Jem
- Subjects
- *
COLON tumors , *SURVIVAL analysis (Biometry) , *TUMOR classification , *DATA analysis , *EVALUATION , *STATISTICS , *DIAGNOSIS ,RECTUM tumors - Abstract
The article presents the authors' response to the article "Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000 – 2007" by CAMILLE MARINGE and others published in a 2013 issue of the periodical. The topics discussed include different types of staging systems used in cancer studies, application of Marigne's method to colorectal carcinoma patients, and one year survival rate of cancer patients.
- Published
- 2014
- Full Text
- View/download PDF
44. 'Get Data Out' Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
- Author
-
van Bodegraven B, Vernon S, Eversfield C, Board R, Craig P, Gran S, Harwood CA, Keohane S, Levell NJ, Matin RN, Proby C, Rajan N, Rous B, Ascott A, Millington GWM, and Venables ZC
- Subjects
- Humans, Incidence, Survival Rate, State Medicine, England epidemiology, Registries, Melanoma, Cutaneous Malignant, Skin Neoplasms epidemiology, Skin Neoplasms pathology, Melanoma epidemiology, Melanoma pathology, Carcinoma, Basal Cell epidemiology, Carcinoma, Basal Cell pathology, Precancerous Conditions
- Abstract
Background: Providing detailed skin cancer statistics, including incidence and survival, by tumour type and patient characteristics is important for up-to-date epidemiological information., Objectives: To create a new clinically relevant consensus-based classification for registered skin tumours using tumour type and patient characteristics and to describe its application to all registered tumours in England between 2013 and 2019., Methods: Tumours with skin topographical codes (ICD-10) and morphology and behaviour (ICD-O3) were grouped together in an iterative process creating a hierarchical tree structure. The primary-level grouping partitioned skin tumours into skin cancer, melanoma in situ, extramammary Paget disease (EMPD) and tumours of uncertain malignant potential. Second-level groups split skin cancer into keratinocyte cancer (KC), melanoma and rare cancers. The third-level group split KC into basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC). Further groups were split into genital or non-genital, first or subsequent tumour, age, gender, stage, or National Health Service (NHS) region. Incidence counts, Kaplan-Meier and net survival estimates and referral routes [two-week wait (TWW), general practitioner (GP), outpatient] categorisations were calculated for each grouping across all years., Results: A total of 1 445 377 skin cancers and 49 123 precancerous lesions and undefined entities were registered in England between 2013 and 2019. Skin tumours and skin cancer incidence rates are increasing for most tumour types. The most common type of skin cancer was BCC with an incidence rate of 282.36 per 100 000 person-years (PYs) [n = 158 934, 95% confidence interval (CI) 280.98-283.76] in 2019, followed by cSCC with an incidence rate of 85.24 per 100 000 PYs (n = 47 977, 95% CI 84.48-86.00) and melanoma with 27.24 (n = 15 332, 95% CI 26.81-27.67) per 100 000 PYs. Each year approximately 1800 rare skin cancers, 1500 genital cSCCs and 100 cases of EMPD are registered. Of 15 000 melanoma cases, 120 cases of melanoma occur in individuals aged < 25 years annually. One-year and five-year overall net survival varies by tumour type. cSCC 5-year net survival (89.8%, 95% CI 88.8-90.9) was comparable to the net survival of all melanomas (89.6%, 95% CI 88.7-90.6). BCC had excellent survival (overall net survival > 100%). Patients with late-stage melanoma, Merkel cell carcinoma and genital cSCC have a 5-year net survival < 60%. Older patients received fewer TWW referrals than their younger counterparts with the same tumour type at the same location. Patients with acral lentiginous melanoma had fewer TWW referrals and more standard GP referrals than patients with common melanomas., Conclusions: 'Get Data Out' Skin provides detailed and up-to-date statistics on all registrable skin tumours in England, including for the first time precancerous lesions and rare subtypes of common cancers. These data can be used by clinicians, researchers and commissioners to better understand skin cancer and improve resource allocation., Competing Interests: Conflicts of interest B.v.B. is an employee of the British Association of Dermatologists. N.J.L. is a trustee of the British Association of Dermatologists. N.R. is a Deputy Editor at the BJD., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.)
- Published
- 2023
- Full Text
- View/download PDF
45. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study.
- Author
-
White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, George G, Russell B, Srirajaskanthan R, and Ramage JK
- Abstract
Background: Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes in survival over time., Methods: A retrospective, population-based study using nationally representative data between 1995 and 2018 from the National Cancer Registry and Analysis Service (NCRAS) in England was conducted on 63,949 tumours. Age-standardized incidence was calculated using Office for National Statistics (ONS) data. Overall survival (OS) was calculated using the Kaplan-Meier estimator. Multivariable analysis was performed using an accelerated failure time model., Findings: Of 63,949 cases, 50.5% (32,309) were female. Age-adjusted incidence increased 3.7-fold between 1995 and 2018 from 2.35 to 8.61 per 100,000. In 2018, highest incidence occurred in lung (1.47 per 100,000), small intestine (1.46 per 100,000), pancreas (1.00 per 100,000) and appendix (0.95 per 100,000). In multivariable analysis, age, sex, morphology, stage, site and deprivation were independent predictors of survival ( p < 0.001). Survival of the entire cohort, and by primary site, is improving over time., Interpretation: NEN incidence continues to rise in England with survival improving over time. Relatively high survival compared to other cancers is an issue for long-term outcomes and funding of care., Funding: Data were extracted and transferred using a grant from Neuroendocrine cancer UK., Competing Interests: JKR supervised securing funding for the grant from Neuroendocrine Cancer UK (NCUK) to process the data in the initial planning of the work. CB states that NCUK receives donation, grant and sponsorship money from patients, businesses and not-for-profit organisations. CB is a board member of the International Neuroendocrine Cancer Alliance (INCA). The other authors declare no conflict of interest., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
46. Histological groups.
- Author
-
Ferlay J and Rous B
- Subjects
- Humans, Incidence, Neoplasms epidemiology
- Published
- 2014
47. Myxofibrosarcomas contain large numbers of infiltrating immature dendritic cells.
- Author
-
Soilleux EJ, Rous B, Love K, Vowler S, Morris LS, Fisher C, and Coleman N
- Subjects
- Biomarkers, Tumor metabolism, Cell Adhesion Molecules metabolism, Cell Count, Dendritic Cells metabolism, Dendritic Cells pathology, Fibrosarcoma metabolism, Histiocytoma, Benign Fibrous metabolism, Histiocytoma, Benign Fibrous pathology, Humans, Immunoenzyme Techniques, Lectins, C-Type metabolism, Myosarcoma metabolism, Receptors, Cell Surface metabolism, Fibrosarcoma pathology, Myosarcoma pathology
- Abstract
Myxofibrosarcoma is a malignant tumor with distinctive histologic features and is believed to be derived from fibroblasts. The function of infiltrating myeloid cells in myxofibrosarcoma is poorly understood. It previously has been shown that a combination of dendritic morphologic features and expression of the C-type lectin, dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN), is useful for identifying DC populations in tissue sections. In the present study, we found that 3% to 61% (median, 22%) of cells in myxofibrosarcomas express DC-SIGN and have dendritic morphologic features. These DC-SIGN--positive cells are not in cell cycle and are consistent with infiltrating DCs. The percentage of DCs in myxofibrosarcomas is independent of tumor grade. It previously has been shown that DC-SIGN--positive cells are either immature DCs or DCs that predominantly activate TH2 cells, both subsets likely to give rise to ineffective antitumor responses. The DC-SIGN--positive DCs that we have identified in myxofibrosarcoma may, therefore, be involved in the induction of ineffective immune responses or even tolerance to tumor antigens.
- Published
- 2003
- Full Text
- View/download PDF
48. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes.
- Author
-
Rous BA, Reaves BJ, Ihrke G, Briggs JA, Gray SR, Stephens DJ, Banting G, and Luzio JP
- Subjects
- Animals, Antigens, CD genetics, Antimalarials metabolism, CD8 Antigens genetics, CD8 Antigens metabolism, Cell Line, Cell Separation, Chloroquine metabolism, Flow Cytometry, Humans, Lysosomal Membrane Proteins, Platelet Membrane Glycoproteins genetics, Protein Sorting Signals, Protein Subunits, Rats, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Tetraspanin 30, Two-Hybrid System Techniques, Adaptor Protein Complex 3 metabolism, Antigens, CD metabolism, Lysosomes metabolism, Platelet Membrane Glycoproteins metabolism, Protein Transport physiology
- Abstract
CD63 is a lysosomal membrane protein that belongs to the tetraspanin family. Its carboxyterminal cytoplasmic tail sequence contains the lysosomal targeting motif GYEVM. Strong, tyrosine-dependent interaction of the wild-type carboxyterminal tail of CD63 with the AP-3 adaptor subunit mu 3 was observed using a yeast two-hybrid system. The strength of interaction of mutated tail sequences with mu 3 correlated with the degree of lysosomal localization of similarly mutated human CD63 molecules in stably transfected normal rat kidney cells. Mutated CD63 containing the cytosolic tail sequence GYEVI, which interacted strongly with mu 3 but not at all with mu 2 in the yeast two-hybrid system, localized to lysosomes in transfected normal rat kidney and NIH-3T3 cells. In contrast, it localized to the cell surface in transfected cells of pearl and mocha mice, which have genetic defects in genes encoding subunits of AP-3, but to lysosomes in functionally rescued mocha cells expressing the delta subunit of AP-3. Thus, AP-3 is absolutely required for the delivery of this mutated CD63 to lysosomes. Using this AP-3-dependent mutant of CD63, we have shown that AP-3 functions in membrane traffic from the trans-Golgi network to lysosomes via an intracellular route that appears to bypass early endosomes.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.